Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-sequencing analysis to identify genes regulated by MYCN in neuroblastoma cell line KCNR.

ABSTRACT: In this study we identified genes regulated by MYCN in KCNR cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE208421 | GEO | 2023/10/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNA-sequencing analysis to identify genes regulated by MYCN in neuroblastoma cell line SHEP by MYCN overexpression

Project description:In this study we identified genes regulated by MYCN in SHEP cells

2023-10-19 | GSE208422 | GEO

RNA-sequencing analysis to identify genes regulated by MYCN, WDR5 and G9a in neuroblastoma cell line IMR32

Project description:In this study we identified genes regulated by MYCN, WDR5 and G9a in IMR32 cells

2023-10-19 | GSE208420 | GEO

RNA-sequencing analysis to identify genes regulated by MYCN in rhabdomyosarcoma cell line RH4

Project description:In this study we identified genes regulated by MYCN in RH4 cells

2023-10-19 | GSE208423 | GEO

MYCN regulated miRNAs

Project description:MYCN regulated miRNAs

| PRJEB6787 | ENA

Identification of genes regulated by MYCN in retinoblastoma (RB) cell line, Y79.

Project description:To determine the downstream genes regulated by MYCN in RB, MYCN was silenced in Y79 cell line, which expressed hign levels of MYCN, using two lentiviral shRNA constructs targetting MYCN.

2021-10-14 | GSE168903 | GEO

RNA-sequencing analysis to investigate genes regulated by HAND2 and MYCN in LAN5 cells

Project description:In this study we identified genes regulated by HAND2 or MYCN or both MYCN and HAND2 in LAN5 cells.

2023-03-29 | GSE183636 | GEO

RNA-sequencing analysis to investigate genes regulated by HAND2 and MYCN in IMR32 cells

Project description:In this study we identified genes regulated by HAND2 or MYCN or both MYCN and HAND2 in IMR32 cells.

2023-03-29 | GSE183609 | GEO

Global transcriptome analysis in the MYCN-amplified neuroblastoma cell line IMR5-75 upon inducible MYCN-knockdown

Project description:Inducible MYCN-knockdown, followed by RNA-seq analysis in the MYCN-amplified neuroblastoma cell line IMR5-75, reveals profound time-dependent transcriptome changes. For modulation of MYCN levels, stable neuroblastoma cell models were used where MYCN can be downregulated via vector-based hairpin RNA induction upon addition of 1Âµg/ml tetracycline (IMR5-75-shMYCN. From cells treated either with tetracycline or solvent (ethanol), RNA was isolated at time points 6 hours, 12 hours and 24 hours. Experiments were done in duplicates. RNA was sequenced.

2016-09-08 | E-GEOD-80397 | biostudies-arrayexpress

Neuroblastoma: MYCN normal vs. MYCN amplified

Project description:To evaluate the expression of genes associated with MYCN in NB, 10 tumors with MYCN amplification and 10 with normal MYCN copy number were subjected to oligonucleotide microarray using Agilent oligo microarray chips. Two-condition experiment, MYCN normal vs. MYCN amplified 10 NB patient tissues for each group.

2013-12-17 | E-GEOD-53371 | biostudies-arrayexpress

Metabolic dependencies in MYCN-driven neuroblastoma

Project description:Here we sought metabolic alterations specifically associated with amplified MYCN as nodes to indirectly target the MYCN oncogene. Liquid chromatography-mass spectrometry-based proteomics identified 7 proteins consistently correlated with MYCN in proteomes from 49 neuroblastoma biopsies and 13 cell lines. Among these were phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in de novo serine synthesis. MYCN associated with two regions in the PHGDH promoter, supporting transcriptional PHGDH regulation by MYCN. Pulsed stable isotope-resolved metabolomics utilizing 13C-glucose labeling demonstrated higher de novo serine synthesis in MYCN-amplified cells compared to cells with diploid MYCN. An independence of MYCN-amplified cells from exogenous serine and glycine was demonstrated by serine and glycine starvation, which attenuated nucleotide pools and proliferation only in cells with diploid MYCN but did not diminish these endpoints in MYCN-amplified cells. Proliferation was attenuated in MYCN-amplified cells by CRISPR/Cas9-mediated PHGDH knockout or treatment with PHGDH small molecule inhibitors without affecting cell viability. PHGDH inhibitors administered as single-agent therapy to NMRI-Foxn1nu/nu mice harboring patient-derived MYCN-amplified neuroblastoma xenografts slowed tumor growth. However, combining a PHGDH inhibitor with the standard-of-care chemotherapy drug, cisplatin, revealed antagonism of chemotherapy efficacy in vivo. Emergence of chemotherapy resistance was confirmed in the genetic PHGDH knockout model in vitro. Altogether, PHDGH knockout and inhibition by small molecules consistently slows proliferation, but stops short of killing the cells, which then establish resistance to classical chemotherapy. Although PHGDH inhibition with small molecules has produced encouraging results in other preclinical cancer models, this approach must be considered with caution in patients with neuroblastoma.

2020-12-11 | PXD018300 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data